Dilipkumar Joshi, MD
Psychiatry · Newark, DENPI 1669565537
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 359 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 28 manufacturers, the largest accounting for just 13.3% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in DE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 359 payments — averaging $17.58 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$841
- Otsuka America Pharmaceutical, Inc.$752
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$587
- Lundbeck LLC$556
- Vanda Pharmaceuticals Inc.$475
- Johnson & Johnson$465
- plus $3K from 22 others
What the payments were for
- Food & beverage$6,278100%
- Education$320%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 50 | $841 |
| Otsuka America Pharmaceutical, Inc. | 45 | $752 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 33 | $587 |
| Lundbeck LLC | 36 | $556 |
| Vanda Pharmaceuticals Inc. | 25 | $475 |
| Johnson & Johnson(2 entities) | 27 | $465 |
| Sunovion Pharmaceuticals Inc. | 22 | $404 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $342 |
| Alkermes, Inc. | 17 | $326 |
| E.r. Squibb & Sons, L.L.C. | 10 | $211 |
| Neurocrine Biosciences, Inc. | 10 | $209 |
| Supernus Pharmaceuticals, Inc. | 12 | $209 |
| Eisai Inc. | 9 | $159 |
| Axsome Therapeutics, Inc. | 7 | $135 |
| Merck | 9 | $123 |
| Teva Pharmaceuticals USA, Inc. | 5 | $89 |
| Jazz Pharmaceuticals Inc. | 4 | $71 |
| Indivior Inc. | 3 | $62 |
| Adlon Therapeutics L.p. | 3 | $52 |
| Almatica Pharma LLC | 2 | $40 |
| Idorsia Pharmaceuticals US Inc | 2 | $39 |
| Tris Pharma Inc | 2 | $33 |
| Braeburn Inc. | 2 | $31 |
| Shire North American Group Inc | 2 | $28 |
| Neuronetics, Inc. | 1 | $24 |
| Corium, LLC | 1 | $17 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
| Arbor Pharmaceuticals, Inc. | 1 | $13 |
How this compares
$6,310 in reported general payments places this provider in the 95th percentile of 114 psychiatry providers in Delaware.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 58 | $69,952 |
| CaplytaLumateperone Tosylate | 25 | $41,506 |
| FanaptIloperidone | 11 | $23,819 |
| VraylarCariprazine Hcl | 17 | $20,133 |
| Divalproex Sodium | 209 | $12,236 |
| TrintellixVortioxetine Hydrobromide | 13 | $9,075 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 213 | $6,576 |
| Trazodone Hcl | 338 | $5,865 |
| Olanzapine | 112 | $5,864 |
| Aripiprazole | 28 | $5,611 |
| Quetiapine Fumarate | 264 | $5,427 |
| Mirtazapine | 192 | $5,235 |
| DayvigoLemborexant | 13 | $4,419 |
| Duloxetine Hcl | 200 | $4,169 |
| Lurasidone Hcl | 14 | $3,745 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Otsuka America Pharmaceutical, Inc.Rexulti | $752 | $69,95258 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $587 | $41,50625 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $475 | $23,81911 claims |
| AbbVieVraylar | $841 | $20,13317 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $342 | $9,07513 claims |
| Eisai Inc.Dayvigo | $159 | $4,41913 claims |
| Almatica Pharma LLCSertraline Hcl | $40 | $96095 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 114 psychiatry providers in Delaware.
Other psychiatry in Newark
- Jeet JoshiNewark$5K
- Alexander JacobsonNewark$4K
- Praful DesaiNewark$2K
- Diana GermosenNewark$883
- Audrey LongsonNewark$876
- Saurabh GuptaNewark$851
- Parth VirojaNewark$369
- Jay WeisbergNewark$185
- Saleem KhanNewark$151
- Ranganathan RamWilmington$202K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.